BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant. 2007;7:1875-1881. [PMID: 17532747 DOI: 10.1111/j.1600-6143.2007.01863.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7:673-687. [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
2 Lao OB, Weissman J, Perkins JD. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant. 2009;23:874-881. [PMID: 19453644 DOI: 10.1111/j.1399-0012.2009.00993.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
3 Nanashima A, Tobinaga S, Masuda J, Miyaaki H, Taura N, Takeshita H, Hidaka S, Sawai T, Nakao K, Nagayasu T. Selecting treatment for hepatocellular carcinoma based on the results of hepatic resection and local ablation therapy. J Surg Oncol 2010;101:481-5. [PMID: 20191611 DOI: 10.1002/jso.21523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
4 O'Connor JK, Trotter J, Davis GL, Dempster J, Klintmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl. 2012;18:949-954. [PMID: 22467602 DOI: 10.1002/lt.23439] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 10.1] [Reference Citation Analysis]
5 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ishikawa T, Itobayashi E, Shimada N, Takaguchi K, Takizawa D. Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. Hepatol Res. 2015;Aug 29; Epub ahead of print. [PMID: 26331402 DOI: 10.1111/hepr.12583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Liu Y, Yang Z, Du F, Yang Q, Hou J, Yan X, Geng Y, Zhao Y, Wang H. Molecular mechanisms of pathogenesis in hepatocellular carcinoma revealed by RNA‑sequencing. Mol Med Rep 2017;16:6674-82. [PMID: 28901494 DOI: 10.3892/mmr.2017.7457] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy MD, Brown DB. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg. 2008;248:617-625. [PMID: 18936575 DOI: 10.1097/sla.0b013e31818a07d4] [Cited by in Crossref: 59] [Cited by in F6Publishing: 78] [Article Influence: 4.5] [Reference Citation Analysis]
8 Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, Ballarin R, Spaggiari M, Tarantino G, D'Amico G, De Santis M, De Pietri L, Troisi RI, Gerunda GE, Di Benedetto F. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 2014;97:220-6. [PMID: 24056629 DOI: 10.1097/TP.0b013e3182a8607e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Said A, Lucey MR. Liver transplantation: an update 2008. Curr Opin Gastroenterol. 2008;24:339-345. [PMID: 18408462 DOI: 10.1097/mog.0b013e3282f8e27e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
10 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
11 Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, Roberts J, Reich DJ, Schwartz ME, Mieles L, Lee FT, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States: Liver Allocation in Patients With HCC. Liver Transpl 2010;16:262-78. [DOI: 10.1002/lt.21999] [Cited by in Crossref: 293] [Cited by in F6Publishing: 234] [Article Influence: 24.4] [Reference Citation Analysis]
12 Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2010;2:348-359. [PMID: 21160806 DOI: 10.4251/wjgo.v2.i9.348] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
13 Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, Shiraki K, Yamada T, Takeda K. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol. 2009;20:217-224. [PMID: 19097810 DOI: 10.1016/j.jvir.2008.10.019] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
14 Kalb B, Chamsuddin A, Nazzal L, Sharma P, Martin DR. Chemoembolization follow-up of hepatocellular carcinoma with MR imaging: usefulness of evaluating enhancement features on one-month posttherapy MR imaging for predicting residual disease. J Vasc Interv Radiol 2010;21:1396-404. [PMID: 20688534 DOI: 10.1016/j.jvir.2010.05.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
15 Tanwar S, Khan SA, Grover VP, Gwilt C, Smith B, Brown A. Liver transplantation for hepatocellular carcinoma. World J Gastroenterol. 2009;15:5511-5516. [PMID: 19938188 DOI: 10.3748/wjg.15.5511] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
16 O'Leary JG, Yachimski PS, Friedman LS. Surgery in the patient with liver disease. Clin Liver Dis. 2009;13:211-231. [PMID: 19442915 DOI: 10.1016/j.cld.2009.02.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
17 Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011;98:1201-1208. [PMID: 21618496 DOI: 10.1002/bjs.7561] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
18 Irtan S, Barbier L, Francoz C, Dondéro F, Durand F, Belghiti J. Liver transplantation for hepatocellular carcinoma: is zero recurrence theoretically possible? Hepatobiliary & Pancreatic Diseases International 2016;15:147-51. [DOI: 10.1016/s1499-3872(16)60069-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Zeng J, Lv L, Mei Z. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2016;40:688-97. [DOI: 10.1016/j.clinre.2016.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
20 Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B, Magnolfi F, Megna AS, Pretolani S, Regine R. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol. 2009;27:2615-2621. [PMID: 19332729 DOI: 10.1200/jco.2008.19.0082] [Cited by in Crossref: 86] [Cited by in F6Publishing: 22] [Article Influence: 7.2] [Reference Citation Analysis]
21 Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010;51:165-73. [DOI: 10.1002/hep.23260] [Cited by in Crossref: 76] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
22 DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13:24-32. [PMID: 21159100 DOI: 10.1111/j.1477-2574.2010.00228.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
23 Heimbach JK. Liver transplantation for hepatocellular carcinoma. Cancer J 2008;14:95-9. [PMID: 18391614 DOI: 10.1097/PPO.0b013e31816a0f6f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 111] [Article Influence: 12.9] [Reference Citation Analysis]
25 Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D;  American Hepato-Pancreato-Biliary Association;  Society of Surgical Oncology;  Society for Surgery of the Alimentary Tract. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12:302-310. [PMID: 20590903 DOI: 10.1111/j.1477-2574.2010.00182.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 7.1] [Reference Citation Analysis]
26 Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, Luo Y, Dong JH. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation. Hepatobiliary Pancreat Dis Int. 2011;10:143-150. [PMID: 21459720 DOI: 10.1016/s1499-3872(11)60023-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Teixeira AC, Mente ED, Castro-e-Silva O, Sankarankutty AK, Cantão CA, Souza FF, Abud D, Muglia V, Elias-Junior J, Martinelli AL. Treatment of hepatocellular carcinoma with liver transplantation: a single-center experience from Brazil. Transplant Proc 2010;42:502-4. [PMID: 20304177 DOI: 10.1016/j.transproceed.2010.01.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R. Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg 2010;34:2146-54. [PMID: 20411387 DOI: 10.1007/s00268-010-0583-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
29 Lee JW, Paeng JC, Kang KW, Kwon HW, Suh K, Chung J, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18 F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. J Nucl Med 2009;50:682-7. [DOI: 10.2967/jnumed.108.060574] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 9.8] [Reference Citation Analysis]
30 Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015;7:1347-54. [PMID: 26052380 DOI: 10.4254/wjh.v7.i10.1347] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
31 Facciuto ME, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 2012;105:692-698. [PMID: 21960321 DOI: 10.1002/jso.22104] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
32 Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26:50-60. [PMID: 23106431 DOI: 10.1111/j.1432-2277.2012.01572.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
33 Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol. 2013;58:609-618. [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021] [Cited by in Crossref: 99] [Cited by in F6Publishing: 85] [Article Influence: 11.0] [Reference Citation Analysis]
34 Vivarelli M, Risaliti A. Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol. 2011;17:4741-4746. [PMID: 22147974 DOI: 10.3748/wjg.v17.i43.4741] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lee SD, Kim SH, Kim SK, Kim YK, Park SJ. Clinical Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma. Transplantation. 2015;99:2142-2149. [PMID: 25905981 DOI: 10.1097/tp.0000000000000719] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
36 Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008;10:60-66. [PMID: 18417044 DOI: 10.1007/s11894-008-0010-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
37 Wong R, Frenette C, Gish R. Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am. 2011;40:599-610. [PMID: 21893276 DOI: 10.1016/j.gtc.2011.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
38 Broering DC, Walter J, Braun F, Rogiers X. Current Status of Hepatic Transplantation. Current Problems in Surgery 2008;45:587-661. [DOI: 10.1067/j.cpsurg.2008.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
39 Levi DM, Nishida S. Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned and Future Directions. Clinics in Liver Disease 2011;15:717-25. [DOI: 10.1016/j.cld.2011.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
40 Levi DM, Tzakis AG, Martin P, Nishida S, Island E, Moon J, Selvaggi G, Tekin A, Madrazo BL, Narayanan G, Garcia MT, Feun LG, Tryphonopoulos P, Skartsis N, Livingstone AS. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg. 2010;210:727-734, 735-736. [PMID: 20421039 DOI: 10.1016/j.jamcollsurg.2010.01.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
41 Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015;15:392. [PMID: 25957784 DOI: 10.1186/s12885-015-1373-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
42 Ogawa K, Kaido T, Okajima H, Fujimoto Y, Yoshizawa A, Yagi S, Hori T, Iida T, Takada Y, Uemoto S. Impact of pretreatments on outcomes after living donor liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2019;26:73-81. [PMID: 30561147 DOI: 10.1002/jhbp.602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
43 Huang X, Lu S. Impact of preoperative locoregional therapy on recurrence and patient survival following liver transplantation for hepatocellular carcinoma: a meta-analysis. Scandinavian Journal of Gastroenterology 2017;52:143-9. [DOI: 10.1080/00365521.2016.1236396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]